Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
CDK4
Name:
cyclin dependent kinase 4
Location:
12q14.1
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT04220892 | Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma | View | |
| NCT04238819 | A Study of Abemaciclib LY2835219 in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors Including Neuroblastoma | View | |
| NCT01907607 | Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib | View | |
| NCT02343172 | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | View | |
| NCT03938337 | Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer | View | |
| NCT03024489 | Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma | View | |
| NCT03434262 | SJDAWN St Jude Childrens Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | View | |
| NCT04594005 | CDK46 Tumor Abemaciclib Paclitaxel | View | |
| NCT00407498 | Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms | View | |
| NCT00408018 | Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms | View | |
| NCT04615312 | A Trail of CDK4 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors | View | |
| NCT01692496 | Activity and Tolerability of Pazopanib in Advanced andor Metastatic Liposarcoma A Phase II Clinical Trial | View | |
| NCT01237236 | A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma | View | |
| NCT02763566 | A Study of Abemaciclib LY2835219 in Participants With Breast Cancer | View | |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | View | |
| NCT04707196 | A Study of Abemaciclib in Indian Women With Advanced Breast Cancer | View | |
| NCT01209598 | PD0332991 Palbociclib in Patients With Advanced or Metastatic Liposarcoma | View | |
| NCT02448420 | Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer | View | |
| NCT03050398 | A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK46 TherapyLEE011Ribociclib | View | |
| NCT02732119 | Study of Ribociclib With Everolimus Exemestane in HR HER2- Locally AdvancedMetastatic Breast Cancer Post Progression on CDK 46 Inhibitor | View | |
| NCT05169567 | Abemaciclib LY2835219 Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer | View | |
| NCT01919229 | A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients MONALEESA-1 | View | |
| NCT01958021 | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast CancerMONALEESA-2 | View | |
| NCT05262400 | A Study to Learn About the Study Medicine Called PF-07220060 in Combination With PF-07104091 In Participants With Breast Cancer and Solid Tumors | View | |
| NCT02187783 | LEE011 for Patients With CDK46 Pathway Activated Tumors SIGNATURE | View | |
| NCT02278120 | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive HER2-negative Advanced Breast Cancer | View | |
| NCT05596409 | ELACESTRANT in Women and Men With CDK46 Inhibitor-Naive Estrogen Receptor Positive HER-2 Negative Metastatic Breast Cancer Study | View | |
| NCT02806648 | A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors pNET | View | |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib LEE011 in Combination With Letrozole for the Treatment of Men and PrePostmenopausal Women With HR HER2- aBC | View | |
| NCT05940493 | Abemaciclib in Newly Diagnosed Meningioma Patients | View | |
| NCT03096912 | A Study Assessing Efficacy Safety of Ribociclib in Patients With Advanced WellDedifferentiated Liposarcoma | View | |
| NCT02530320 | Safety and Efficacy of PD0332991 Palbociclib a Cyclin-dependent Kinase 4 and 6 Inhibitor in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved | View | |
| NCT03515200 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | View | |
| NCT06267963 | A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults | View | |
| NCT06390839 | Testing Palbociclib PD-0332991 as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification MATCH - Subprotocol Z1C | View | |
| NCT06570031 | ONO-4578-06Phase I Study of ONO-4578 and Letrozole Plus CDK4 6 Inhibitors in Breast Cancer | View | |
| NCT04275050 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets | View | |
| NCT06001762 | TRADE Dose Escalation Tolerability of Abemaciclib in HR HER2- Early Stage Breast Cancer | View | |
| NCT04391595 | LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | View | |
| NCT04408924 | Abemaciclib LY2835219 in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer | View | |
| NCT04439201 | Testing Palbociclib PD-0332991 as a Potential Targeted Treatment in Cancers With CCND1 2 3 Amplification MATCH-Subprotocol Z1B | View | |
| NCT06120283 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | View | |
| NCT05288166 | A Study of Abemaciclib LY2835219 With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment Metastatic Hormone-Sensitive Prostate Cancer | View | |
| NCT05766410 | A Randomized Study Comparing the Immune Modulation Effect of Ribociclib Palbociclib and Abemaciclib in ERHER2- EBC | View | |
| NCT05905341 | Study of PF-07224826 as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors | View | |
| NCT05923411 | A Study for Multiple Tablet Forms of The Study Medicine PF-07220060 in Healthy Adults | View | |
| NCT05935748 | Ph2 Study NKT2152 With Palbociclib Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma ccRcc | View | |
| NCT06113809 | Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma UPS | View | |
| NCT06253195 | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HRHER2- Breast Cancer and Other Advanced Solid Tumors | View | |
| NCT06351644 | ON 123300 Narazaciclib and Dexamethasone in Patients With Relapsed andor Refractory Multiple Myeloma | View | |
| NCT06478927 | Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib | View | |
| NCT02422615 | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer | View | |
| NCT06612814 | PARP Inhibitor With CDK4 6 Inhibitor and Endocrine Therapy in HR HER2-Advanced Breast Cancer | View | |
| NCT02571829 | A Phase II Study Assessing Efficacy Safety of Ribociclib in Patients With Advanced WellDedifferentiated Liposarcoma | View | |
| NCT04031885 | A Study of Abemaciclib LY2835219 in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive HER2 Negative Metastatic Breast Cancer | View | |
| NCT06362980 | A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations | View | |
| NCT03965845 | A Study of Telaglenastat CB-839 in Combination With Palbociclib in Patients With Solid Tumors | View | |
| NCT02831530 | Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib LY2835219 in Early Breast Cancer Patients | View | |
| NCT00339404 | Genetic Analysis of Familial Melanoma | View | |
| NCT03242382 | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression | View | |
| NCT03283384 | Tailoring NEOadjuvant Therapy in Hormone Receptor Positive HER2 Negative Luminal Breast Cancer | View | |
| NCT03310879 | Study of the CDK46 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 | View | |
| NCT03439046 | Study of the Molecular Features of Postmenopausal Women With HR HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and in Patients With a PIK3CA Mutation on Second-line Treatment With Alpelisib Plus Fulvestrant | View | |
| NCT03454919 | Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations | View |